Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
The Motley Fool July 17, 2009 Brian Orelli	Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson.
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool June 28, 2011 Brian Orelli	HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments.
The Motley Fool August 12, 2011 David Williamson	Does "FDA" Stand for "Faster Drug Approvals"? FDA approvals for 2011 just surpassed 2010.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
The Motley Fool September 20, 2011 Brian Orelli	Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell?
The Motley Fool July 21, 2010 Brian Orelli	15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
The Motley Fool April 22, 2009 Brian Orelli	Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
The Motley Fool July 16, 2011 Melly Alazraki	HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales.
The Motley Fool September 19, 2008 Brian Lawler	FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
The Motley Fool July 22, 2009 Brian Orelli	Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences.
The Motley Fool December 21, 2004 Brian Gorman	Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients.
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
The Motley Fool October 7, 2011 Brian Orelli	A Little Help, Please Gilead pumps up the pipeline.
The Motley Fool January 28, 2009 Brian Orelli	Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool December 11, 2009 Brian Orelli	Gilead Gets the Experts on Its Side An advisory committee says yes after the FDA said no.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
The Motley Fool March 20, 2008 Brian Lawler	Gilead Not Slowing Gilead Sciences gets a new approval for a drug.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool July 23, 2007 Brian Lawler	Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
BusinessWeek September 18, 2006 Gene G. Marcial	Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted.
The Motley Fool September 6, 2007 Brian Lawler	Foolish Fantasy Football: Gilead Sciences on Offense For his fantasy football investment team, this stock analyst thinks Gilead packs enough offensive muscle to score in anyone's portfolio.
The Motley Fool June 25, 2010 Brian Orelli	Diversification Times 50,000 Gilead Sciences diversifies any way it can.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
The Motley Fool June 12, 2008 Brian Lawler	Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
BusinessWeek April 25, 2005 Sarah Lacy	BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.